Genetic culprit in pancreatic cancer risk identified

Share this article:

Mutations in the ATM gene may raise a person's hereditary risk for pancreatic cancer, information that could lead to better screening methods for the disease, researchers have learned.

Approximately 10% of people with pancreatic cancer come from families with multiple cases of the disease. To confirm the suspicion that this clustering was genetically based, a team led by Alison Klein, PhD, director of the National Familial Pancreas Tumor Registry at The Johns Hopkins Hospital in Baltimore, Maryland, sought to identify ATM gene mutations in persons with and without pancreatic cancer.

Using whole genome and whole exome analyses, the researchers learned that 4 of 166 persons (2.4%) with pancreatic cancer had the ATM mutations, but 190 spousal control subsets did not. Among the 87 most severely affected families—those with three or more cases of pancreatic cancer—four mutations were found (4.6%).

Although the genes responsible for the majority of cases of familial pancreatic ductal adenocarcinoma remain unknown, “Our results indicate that inherited ATM mutations play an important role in familial pancreatic cancer predisposition” wrote Klein and colleagues in their report for Cancer Discovery (http://cancerdiscovery.aacrjournals.org/content/early/2011/12/23/2159-8290.CD-11-0194.full.pdf+html?sid=c4047f1c-af1d-437e-8a9b-0e98de86fe33). They also noted that the identification of these mutations has substantial implications for risk assessment and surveillance in family members of people with pancreatic cancer.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Improved tyrosine kinase inhibitor (TKI) selectively activates in tumor tissue, minimizing side ...

A new strategy developed by an interdisciplinary team of researchers aims to reduce the side effects connected to use of tyrosine kinase inhibitors (TKIs).

Prior cancer exclusion criteria may stymie potential of lung cancer clinical trials

A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.

Better adherence to guidelines for safe handling of antineoplastic drugs is needed

Recommended safe handling practices for workers who administer antineoplastic drugs in health care settings are not always followed, according to a new study.